AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Add Yahoo as a preferred source to see more of our stories on Google. Woman’s World has affiliate partnerships. We receive compensation when you click on a link and make a purchase. Learn more! Sure, ...

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, and the American Lung Association are ...

NEW JERSEY (Ivanhoe Newswire) – According to the Centers for Disease Control and Prevention, COPD, or chronic obstructive pulmonary disease was the sixth leading cause of death in the U.S. in 2020.

AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...

Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...

Are you finding that your chronic obstructive pulmonary disease (COPD) is making it harder to do the things you enjoy? Canceling plans more often? Missing work due to flare-ups? It could mean your ...

The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), drugmaker GSK announced on Thursday. Labeling for the interleukin-5 (IL-5) ...

It seems patient satisfaction is low when it comes to their chronic obstructive pulmonary disease (COPD) treatment, according to a recent report out from consultancy Phreesia Life Sciences. When ...

Please provide your email address to receive an email when new articles are posted on . The FDA based mepolizumab’s approval on phase 3 MATINEE and METREX trial results. Mepolizumab has been assessed ...